Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kissei to Run Additional PIII for Spinocerebellar Degeneration Drug
Kissei Pharmaceutical said on March 14 that it has launched an additional PIII study for its spinocerebellar degeneration treatment rovatirelin after the drug’s filing was pulled in 2023 due to insufficient data. The trial this time is a placebo-controlled double-blind…
To read the full story
Related Article
- Kissei Pulls Japan NDA for Spinocerebellar Degeneration Treatment
July 20, 2023
- Kissei Files Rovatirelin for Spinocerebellar Degeneration in Japan
December 24, 2021
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
- Meiji Launches Rezurock in Thailand
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…